Document is current
Any future updates will be listed below
-
Authors
Wojnarowicz, Paulina M.
Escolano, Marta Garcia
Huang, Yun-Han
Desai, Bina
Chin, Yvette
Shah, Riddhi
Xu, Sijia
Yadav, Saurabh
Yaklichkin, Sergey
Ouerfelli, Ouathek
Soni, Rajesh Kumar
Philip, John https://orcid.org/0000-0002-0535-7178
Montrose, David C.
Healey, John H.
Rajasekhar, Vinagolu K.
Garland, William A.
Ratiu, Jeremy
Zhuang, Yuan
Norton, Larry
Rosen, Neal
Hendrickson, Ronald C.
Zhou, Xi Kathy https://orcid.org/0000-0002-8942-439X
Iavarone, Antonio https://orcid.org/0000-0002-0683-4634
Massague, Joan
Dannenberg, Andrew J. https://orcid.org/0000-0002-1901-6497
Lasorella, Anna
Benezra, Robert https://orcid.org/0000-0002-6031-6870
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
Botwinick-Wolfensohn Foundation
Fonds de Recherche du Québec - Nature et Technologies
Please note all funding is listed in the acknowledgements. Every time I update the submission the funding sources get lost.
- License Information
-
More Information
Article History
Received: 3 November 2020
Accepted: 15 April 2021
First Online: 24 May 2021
Competing interests
: R.B. and W.A.G. own shares of Angiogenex, Inc., which holds the patent for the use and development of AGX51. R.B. is the Chair of the Scientific Advisory Board (SAB) of Angiogenex, Inc. and a Board Member, both positions unpaid. O.O. is listed as an inventor and receives royalties from Patents that were filed by MSKCC. O.O. is an unpaid Member of the SAB of Angiogenex, Inc. and owns shares in Angiogenex, Inc.
